Jubilant Pharmova Limited has announced that the U.S. Food and Drug Administration (USFDA) has granted approval for the commercial batch manufacturing of a new product. This approval pertains to Line 3 at the Jubilant HollisterStier LLC contract manufacturing facility in Spokane, USA. This marks a significant milestone for the company’s contract manufacturing capabilities and expands its service offerings for pharmaceutical and biopharmaceutical clients.
USFDA Greenlights New Manufacturing Capability
Jubilant Pharmova Limited announced today that its subsidiary, Jubilant HollisterStier LLC (JHS), has received approval from the U.S. Food and Drug Administration (USFDA) for its new Isolator-based Line 3 at its contract manufacturing facility in Spokane, Washington, USA. This approval enables the commercial batch manufacturing of the first product on this newly established line.
Strategic Expansion in Contract Manufacturing
The USFDA clearance for Line 3 at JHS is a crucial development for Jubilant Pharmova’s contract manufacturing business. Jubilant HollisterStier LLC is a leading integrated contract manufacturer specializing in sterile injectables and ophthalmics. The new line’s approval is expected to enhance JHS’s capacity and capability to serve pharmaceutical and biopharmaceutical industries, streamlining manufacturing processes from qualification through commercial release.
Jubilant HollisterStier LLC is a subsidiary of Jubilant Pharma Holding Inc., which is in turn a subsidiary of Jubilant Pharma Limited, Singapore, ultimately a wholly owned subsidiary of Jubilant Pharmova Limited. This expansion underscores the company’s commitment to strengthening its global pharmaceutical services portfolio and catering to regulated markets.
Source: BSE
